Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab InjectionsUnusual Whales·Aug 9 at 07:48 PM02493+0.36%688062-5.04%
Mabwell passes Brazil ANVISA GMP inspection for denosumab biosimilarsPUBT·Aug 9 at 07:00 PM02493+0.36%688062-5.04%
Mabwell says China NMPA clears 9MW5211 vitiligo trial applicationPUBT·Jul 15 at 07:03 AM02493+0.36%688062-5.04%
Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancersPUBT·Jun 23 at 07:00 PM688062-5.04%02493+0.36%
Mabwell Showcases Promising Nectin-4 ADC Data in Cervical Cancer at ESMO Gynae 2026Tip Ranks·Jun 18 at 09:43 AM688062-5.04%02493+0.36%
Mabwell's ESG rating upgraded to A, with a composite score of 7.28, leading the pharmaceutical industry rating同壁财经·Jun 3 at 05:40 AM688062-5.04%
23:30 ETMabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentationsprnewswire·May 21 at 10:32 PM688062-5.04%02493+0.36%
